InsiderTrades

Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.

Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-01 · accession 0001439222-24-000048 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-03-05 2024-03-05 AGIO Goff Brian CEO, Dir S - Sale+OE $32.57 -4,156 53.8K -7% -$135.4K
D 2024-03-05 2024-03-01 AGIO Goff Brian CEO, Dir M - OptEx $0.00 +8,500 57.9K +17% $0
D 2024-03-05 2024-03-01 AGIO Goff Brian CEO, Dir M - OptEx $0.00 -8,500 17.0K -33% $0
DM 2024-03-05 2024-03-01 AGIO Goff Brian CEO, Dir A - Grant $0.00 +249.5K 195.5K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common stock 2024-03-05 S D 4,156 $32.57 53,780 D — —
2 Common Common stock 2024-03-01 M A 8,500 $0.00 57,936 D — —
3 Derivative Restricted stock units 2024-03-01 M D 8,500 $0.00 17,000 D — · — to — 8,500 Common stock (F2) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F5) The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
4 Derivative Restricted stock units 2024-03-01 A A 54,000 $0.00 54,000 D — · — to — 54,000 Common stock (F2) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F3) The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
5 Derivative Stock options (right to buy) 2024-03-01 A A 195,500 $0.00 195,500 D $32.27 · — to 2034-03-01 195,500 Common stock (F4) This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter.